Press releases

18 March, 2015

Regulatory

NeuroVive Pharmaceutical publishes English version of annual report for 2014

NeuroVive Pharmaceutical AB (publ) today announced that the English version of the annual report for 2014 is now available on the company's website www.neurovive.com.The annual report can also be acce ...

18 February, 2015

Regulatory

NeuroVive: Year-End Report 1 Jan. 2014 till 31 Dec. 2014

Fourth Quarter (1 Oct. 2014 - 31 Dec. 2014) · Net revenues were SEK 0 (0) and other operating income was SEK 8,000 (12,000). · Loss before tax was SEK -17,346,000 (9,169,000). · Earnings per share* we ...

19 November, 2014

Regulatory

NeuroVive: Interim Report 1 Jan. 2014 to 30 Sep. 2014

Important outlicensing deal and increased focus on core operations

20 August, 2014

Regulatory

NeuroVive: Interim Report 1 Jan. 2014 to 30 Jun. 2014

NeuroVive's research wins award at international research symposium

9 May, 2014

Regulatory

NeuroVive: Interim report 1 Jan. 2014 till 31 Mar. 2014

Successful rights issue and final patient treated in phase III study on CicloMulsion®

17 April, 2014

Regulatory

NeuroVive Pharmaceutical’s 2013 Annual Report now available

Today, NeuroVive Pharmaceutical AB (publ) announced that the Annual Report for 2013 is available as PDF at www.neurovive.com, and can be read via the link below. The available report is in Swedish. An ...

19 February, 2014

Regulatory

NeuroVive: Year-End Report 1 Jan. 2013 till 31 Dec. 2013

NeuroVive consolidates positioning as leading mitochondrial medicine company

20 November, 2013

Regulatory

NeuroVive: Interim Report 1 Jan. 2013 till 30 Sep. 2013

Increased interest in NeuroVives product portfolio with cyclophilin inhibitors and energy regulators

23 August, 2013

Regulatory

NeuroVive: Interim Report 1 Jan. 2013 till 30 Jun. 2013

Milestones achieved consolidate positioning in mitochondrial medicine Six months (1 Jan. 2013 - 30 Jun. 2013) · Net revenues were SEK 5,335,000 (0) and other operating income was SEK 863,000 (31 ...

24 May, 2013

Regulatory

NeuroVive: Interim report 1 Jan. 2013 till 31 Mar. 2013

The listing on Nasdaq OMX creates possibilities for the future